

**PHARMACEUTICALS**  
**WORLDWIDE NET REVENUE BY PRODUCTS**  
**FOURTH QUARTER 2001**  
(000's)

	DOMESTIC				FOREIGN				TOTAL			
	4TH QTR 2001	4TH QTR 2000	DOLLAR CHANGE	PERCENT CHANGE	4TH QTR 2001	4TH QTR 2000	DOLLAR CHANGE	PERCENT CHANGE	4TH QTR 2001	4TH QTR 2000	DOLLAR CHANGE	PERCENT CHANGE
PREMARIN FAMILY	\$ 353,437	\$ 274,069	\$ 79,368	28.96%	\$ 74,187	\$ 68,807	\$ 5,380	7.82%	\$ 427,624	\$ 342,876	\$ 84,748	24.72%
EFFEXOR	348,225	202,326	145,899	72.11%	126,988	89,482	37,506	41.91%	475,213	291,808	183,405	62.85%
PREVNAR	208,971	211,110	(2,139)	(1.01)%	16,823	-	16,823	100.00%	225,794	211,110	14,684	6.96%
INFANT NUTRITIONALS	-	-	-	-	178,538	179,181	(643)	(0.36)%	178,538	179,181	(643)	(0.36)%
ORAL CONTRACEPTIVES (excluding Alesse)	45,206	51,664	(6,458)	(12.50)%	98,845	92,150	6,695	7.27%	144,051	143,814	237	0.16%
PROTONIX	107,268	80,027	27,241	34.04%	-	-	-	-	107,268	80,027	27,241	34.04%
ZOSYN/ TAZOCIN	63,372	59,704	3,668	6.14%	52,322	46,456	5,866	12.63%	115,694	106,160	9,534	8.98%
ZOTON	-	-	-	-	77,359	59,981	17,378	28.97%	77,359	59,981	17,378	28.97%
CORDARONE	73,412	77,635	(4,223)	(5.44)%	1,157	1,236	(79)	(6.39)%	74,569	78,871	(4,302)	(5.45)%
ATIVAN	7,820	6,851	969	14.14%	45,808	42,562	3,246	7.63%	53,628	49,413	4,215	8.53%
BENEFIX	43,016	38,154	4,862	12.74%	4,838	4,483	355	7.92%	47,854	42,637	5,217	12.24%
SYNVISIC	40,217	37,283	2,934	7.87%	3,933	3,304	629	19.04%	44,150	40,587	3,563	8.78%
REFACTO	7,318	-	7,318	100.00%	29,889	23,493	6,396	27.23%	37,207	23,493	13,714	58.37%
ALESSE	33,773	30,481	3,292	10.80%	8,408	6,375	2,033	31.89%	42,181	36,856	5,325	14.45%
FACTOR VIII	29,980	22,545	7,435	32.98%	-	-	-	-	29,980	22,545	7,435	32.98%
MINOCIN	5,591	6,708	(1,117)	(16.65)%	28,785	27,281	1,504	5.51%	34,376	33,989	387	1.14%
ENBREL	-	-	-	-	30,814	13,772	17,042	123.74%	30,814	13,772	17,042	123.74%
SONATA	3,527	10,577	(7,050)	(66.65)%	1,096	1,604	(508)	(31.67)%	4,623	12,181	(7,558)	(62.05)%
RAPAMUNE	17,318	9,495	7,823	82.39%	4,059	405	3,654	902.22%	21,377	9,900	11,477	115.93%
MYLOTARG	7,789	7,601	188	2.47%	-	-	-	-	7,789	7,601	188	2.47%
NEUMEGA	7,941	7,153	788	11.02%	352	664	(312)	(46.99)%	8,293	7,817	476	6.09%
<i>subtotal</i>	<i>1,404,181</i>	<i>1,133,383</i>	<i>270,798</i>	<i>23.89%</i>	<i>784,201</i>	<i>661,236</i>	<i>122,965</i>	<i>18.60%</i>	<i>2,188,382</i>	<i>1,794,619</i>	<i>393,763</i>	<i>21.94%</i>
<b>OTHER PHARMACEUTICALS:</b>												
GENERIC	41,674	95,162	(53,488)	(56.21)%	-	-	-	-	41,674	95,162	(53,488)	(56.21)%
MENINGITEC	-	-	-	-	19,605	87,659	(68,054)	(77.63)%	19,605	87,659	(68,054)	(77.63)%
ZIAC / ZEBETA	6,676	66,987	(60,311)	(90.03)%	9,348	9,922	(574)	(5.79)%	16,024	76,909	(60,885)	(79.16)%
OTHER	202,714	192,242	10,472	5.45%	229,285	252,056	(22,771)	(9.03)%	431,999	444,298	(12,299)	(2.77)%
<i>subtotal</i>	<i>251,064</i>	<i>354,391</i>	<i>(103,327)</i>	<i>(29.16)%</i>	<i>258,238</i>	<i>349,637</i>	<i>(91,399)</i>	<i>(26.14)%</i>	<i>509,302</i>	<i>704,028</i>	<i>(194,726)</i>	<i>(27.66)%</i>
ALLIANCE REVENUE	118,782	61,144	57,638	94.27%	-	-	-	-	118,782	61,144	57,638	94.27%
<b>TOTAL WYETH-AYERST</b>	<b>1,774,027</b>	<b>1,548,918</b>	<b>225,109</b>	<b>14.53%</b>	<b>1,042,439</b>	<b>1,010,873</b>	<b>31,566</b>	<b>3.12%</b>	<b>2,816,466</b>	<b>2,559,791</b>	<b>256,675</b>	<b>10.03%</b>
FORT DODGE	110,644	114,833	(4,189)	(3.65)%	105,929	115,386	(9,457)	(8.20)%	216,573	230,219	(13,646)	(5.93)%
<b>TOTAL PHARMACEUTICALS</b>	<b>\$ 1,884,671</b>	<b>\$ 1,663,751</b>	<b>\$ 220,920</b>	<b>13.28%</b>	<b>\$ 1,148,368</b>	<b>\$ 1,126,259</b>	<b>\$ 22,109</b>	<b>1.96%</b>	<b>\$ 3,033,039</b>	<b>\$ 2,790,010</b>	<b>\$ 243,029</b>	<b>8.71%</b>

**CONSUMER HEALTH CARE**  
**WORLDWIDE NET REVENUE BY PRODUCTS**  
**FOURTH QUARTER 2001**  
(000's)

	DOMESTIC				FOREIGN				TOTAL			
	4TH QTR 2001	4TH QTR 2000	DOLLAR CHANGE	PERCENT CHANGE	4TH QTR 2001	4TH QTR 2000	DOLLAR CHANGE	PERCENT CHANGE	4TH QTR 2001	4TH QTR 2000	DOLLAR CHANGE	PERCENT CHANGE
<b>ADVIL FAMILY</b>	\$ 146,544	\$ 131,497	\$ 15,047	11.44%	\$ 26,572	\$ 24,942	\$ 1,630	6.54%	\$ 173,116	\$ 156,439	\$ 16,677	10.66%
<b>CENTRUM</b>	90,544	87,180	3,364	3.86%	46,929	45,204	1,725	3.82%	137,473	132,384	5,089	3.84%
<b>ROBITUSSIN</b>	81,593	100,050	(18,457)	(18.45)%	10,522	9,358	1,164	12.44%	92,115	109,408	(17,293)	(15.81)%
<b>CALTRATE</b>	18,616	12,767	5,849	45.81%	26,066	18,105	7,961	43.97%	44,682	30,872	13,810	44.73%
<b>CHAPSTICK</b>	42,154	43,379	(1,225)	(2.82)%	5,123	4,394	729	16.59%	47,277	47,773	(496)	(1.04)%
<b>DIMETAPP</b>	22,236	36,633	(14,397)	(39.30)%	12,278	10,258	2,020	19.69%	34,514	46,891	(12,377)	(26.40)%
<b>SOLGAR</b>	14,099	16,273	(2,174)	(13.36)%	8,670	9,347	(677)	(7.24)%	22,769	25,620	(2,851)	(11.13)%
<b>OTHER</b>	62,952	62,055	897	1.45%	78,731	86,547	(7,816)	(9.03)%	141,683	148,602	(6,919)	(4.66)%
<b>TOTAL CONSUMER HEALTH CARE</b>	<b>\$ 478,738</b>	<b>\$ 489,834</b>	<b>\$ (11,096)</b>	<b>(2.27)%</b>	<b>\$ 214,891</b>	<b>\$ 208,155</b>	<b>\$ 6,736</b>	<b>3.24%</b>	<b>\$ 693,629</b>	<b>\$ 697,989</b>	<b>\$ (4,360)</b>	<b>(0.62)%</b>

AHPC  
**WORLDWIDE NET REVENUE BY PRODUCTS**  
**FOURTH QUARTER 2001**  
(000's)

	DOMESTIC				FOREIGN				TOTAL			
	4TH QTR 2001	4TH QTR 2000	DOLLAR CHANGE	PERCENT CHANGE	4TH QTR 2001	4TH QTR 2000	DOLLAR CHANGE	PERCENT CHANGE	4TH QTR 2001	4TH QTR 2000	DOLLAR CHANGE	PERCENT CHANGE
<b>TOTAL PHARMACEUTICALS</b>	\$ 1,884,671	\$ 1,663,751	\$ 220,920	13.28%	\$ 1,148,368	\$ 1,126,259	\$ 22,109	1.96%	\$ 3,033,039	\$ 2,790,010	\$ 243,029	8.71%
<b>TOTAL CONSUMER HEALTH CARE</b>	478,738	489,834	(11,096)	(2.27)%	214,891	208,155	6,736	3.24%	693,629	697,989	(4,360)	(0.62)%
<b><i>TOTAL HEALTH CARE</i></b>	<b>\$ 2,363,409</b>	<b>\$ 2,153,585</b>	<b>\$ 209,824</b>	<b>9.74%</b>	<b>\$ 1,363,259</b>	<b>\$ 1,334,414</b>	<b>\$ 28,845</b>	<b>2.16%</b>	<b>\$ 3,726,668</b>	<b>\$ 3,487,999</b>	<b>\$ 238,669</b>	<b>6.84%</b>

Note: The 2000 amounts have been restated in order to reflect the deconsolidation of Immunex, alliance revenue relating to co-promotion agreements between the Company and Immunex, and adoption of authoritative guidance reflecting certain rebates and sales incentives as reductions of revenues instead of selling and marketing expenses. In addition, certain other reclassification adjustments have been made in 2000 in order to conform to the 2001 presentation. In addition, for presentation purposes, the format of the report as it relates to pharmaceuticals has been modified, however, all products previously identified continue to be disclosed on the report. Ziact / Zebeta and generic products previously classified as "other" are now shown separately as a component of other.

**PHARMACEUTICALS**  
**WORLDWIDE NET REVENUE BY PRODUCTS**  
**TWELVE MONTHS ENDED DECEMBER 31, 2001**  
(000's)

	DOMESTIC				FOREIGN				TOTAL			
	YTD 2001	YTD 2000	DOLLAR CHANGE	PERCENT CHANGE	YTD 2001	YTD 2000	DOLLAR CHANGE	PERCENT CHANGE	YTD 2001	YTD 2000	DOLLAR CHANGE	PERCENT CHANGE
PREMARIN FAMILY	\$ 1,795,558	\$ 1,598,416	\$ 197,142	12.33%	\$ 277,967	\$ 271,805	6,162	2.27%	\$ 2,073,525	\$ 1,870,221	\$ 203,304	10.87%
EFFEXOR	1,097,515	831,862	265,653	31.93%	444,501	327,226	117,275	35.84%	1,542,016	1,159,088	382,928	33.04%
PREVNAR	767,479	460,586	306,893	66.63%	30,731	-	30,731	100.00%	798,210	460,586	337,624	73.30%
INFANT NUTRITIONALS	-	-	-	-	731,168	690,794	40,374	5.84%	731,168	690,794	40,374	5.84%
ORAL CONTRACEPTIVES (excluding Alesse)	197,414	244,176	(46,762)	(19.15)%	365,164	366,307	(1,143)	(0.31)%	562,578	610,483	(47,905)	(7.85)%
PROTONIX	561,261	145,004	416,257	287.07%	-	-	-	-	561,261	145,004	416,257	287.07%
ZOSYN/TAZOCIN	240,252	215,322	24,930	11.58%	186,630	169,190	17,440	10.31%	426,882	384,512	42,370	11.02%
ZOTON	-	-	-	-	284,061	233,858	50,203	21.47%	284,061	233,858	50,203	21.47%
CORDARONE	265,058	193,847	71,211	36.74%	4,545	9,310	(4,765)	(51.18)%	269,603	203,157	66,446	32.71%
ATIVAN	57,900	63,547	(5,647)	(8.89)%	174,762	182,551	(7,789)	(4.27)%	232,662	246,098	(13,436)	(5.46)%
BENEFIX	191,903	161,872	30,031	18.55%	20,893	18,171	2,722	14.98%	212,796	180,043	32,753	18.19%
SYNVISC	172,890	167,810	5,080	3.03%	15,387	11,459	3,928	34.28%	188,277	179,269	9,008	5.02%
REFACTO	31,220	-	31,220	100.00%	116,039	91,085	24,954	27.40%	147,259	91,085	56,174	61.67%
ALESSE	109,330	103,329	6,001	5.81%	31,504	24,717	6,787	27.46%	140,834	128,046	12,788	9.99%
FACTOR VIII	129,195	89,767	39,428	43.92%	-	-	-	-	129,195	89,767	39,428	43.92%
MINOCIN	14,584	20,295	(5,711)	(28.14)%	107,543	126,879	(19,336)	(15.24)%	122,127	147,174	(25,047)	(17.02)%
ENBREL	-	-	-	-	93,851	37,641	56,210	149.33%	93,851	37,641	56,210	149.33%
SONATA	84,581	69,170	15,411	22.28%	4,237	4,781	(544)	(11.38)%	88,818	73,951	14,867	20.10%
RAPAMUNE	61,231	25,500	35,731	140.12%	8,954	950	8,004	842.53%	70,185	26,450	43,735	165.35%
MYLOTARG	30,125	20,193	9,932	49.19%	-	-	-	-	30,125	20,193	9,932	49.19%
NEUMEGA	27,534	32,568	(5,034)	(15.46)%	1,605	1,298	307	23.65%	29,139	33,866	(4,727)	(13.96)%
<i>subtotal</i>	<i>5,835,030</i>	<i>4,443,264</i>	<i>1,391,766</i>	<i>31.32%</i>	<i>2,899,542</i>	<i>2,568,022</i>	<i>331,520</i>	<i>12.91%</i>	<i>8,734,572</i>	<i>7,011,286</i>	<i>1,723,286</i>	<i>24.58%</i>
<b>OTHER PHARMACEUTICALS:</b>												
GENERIC	338,308	471,591	(133,283)	(28.26)%	-	-	-	-	338,308	471,591	(133,283)	(28.26)%
MENINGITEC	-	-	-	-	78,610	322,575	(243,965)	(75.63)%	78,610	322,575	(243,965)	(75.63)%
ZIAC / ZEBETA	33,044	239,284	(206,240)	(86.19)%	36,842	44,414	(7,572)	(17.05)%	69,886	283,698	(213,812)	(75.37)%
OTHER	463,870	671,724	(207,854)	(30.94)%	932,666	1,030,432	(97,766)	(9.49)%	1,396,536	1,702,156	(305,620)	(17.95)%
<i>subtotal</i>	<i>835,222</i>	<i>1,382,599</i>	<i>(547,377)</i>	<i>(39.59)%</i>	<i>1,048,118</i>	<i>1,397,421</i>	<i>(349,303)</i>	<i>(25.00)%</i>	<i>1,883,340</i>	<i>2,780,020</i>	<i>(896,680)</i>	<i>(32.25)%</i>
ALLIANCE REVENUE	322,357	188,307	134,050	71.19%	-	-	-	-	322,357	188,307	134,050	71.19%
<b>TOTAL WYETH-AYERST</b>	<b>6,992,609</b>	<b>6,014,170</b>	<b>978,439</b>	<b>16.27%</b>	<b>3,947,660</b>	<b>3,965,443</b>	<b>(17,783)</b>	<b>(0.45)%</b>	<b>10,940,269</b>	<b>9,979,613</b>	<b>960,656</b>	<b>9.63%</b>
FORT DODGE	378,337	369,021	9,316	2.52%	397,849	423,938	(26,089)	(6.15)%	776,186	792,959	(16,773)	(2.12)%
<b>TOTAL PHARMACEUTICALS</b>	<b>\$ 7,370,946</b>	<b>\$ 6,383,191</b>	<b>\$ 987,755</b>	<b>15.47%</b>	<b>\$ 4,345,509</b>	<b>\$ 4,389,381</b>	<b>\$ (43,872)</b>	<b>(1.00)%</b>	<b>\$ 11,716,455</b>	<b>\$ 10,772,572</b>	<b>\$ 943,883</b>	<b>8.76%</b>

**CONSUMER HEALTH CARE**  
**WORLDWIDE NET REVENUE BY PRODUCTS**  
**TWELVE MONTHS ENDED DECEMBER 31, 2001**  
(000's)

	DOMESTIC				FOREIGN				TOTAL			
	YTD 2001	YTD 2000	DOLLAR CHANGE	PERCENT CHANGE	YTD 2001	YTD 2000	DOLLAR CHANGE	PERCENT CHANGE	YTD 2001	YTD 2000	DOLLAR CHANGE	PERCENT CHANGE
ADVIL FAMILY	\$ 500,948	\$ 490,366	\$ 10,582	2.16%	\$ 95,929	\$ 88,888	\$ 7,041	7.92%	\$ 596,877	\$ 579,254	\$ 17,623	3.04%
CENTRUM	359,515	359,520	(5)	(0.00)%	167,796	157,515	10,281	6.53%	527,311	517,035	10,276	1.99%
ROBITUSSIN	234,533	237,778	(3,245)	(1.36)%	32,779	31,648	1,131	3.57%	267,312	269,426	(2,114)	(0.78)%
CALTRATE	67,366	59,819	7,547	12.62%	84,139	76,357	7,782	10.19%	151,505	136,176	15,329	11.26%
CHAPSTICK	117,733	103,851	13,882	13.37%	15,790	13,966	1,824	13.06%	133,523	117,817	15,706	13.33%
DIMETAPP	77,830	91,495	(13,665)	(14.94)%	28,125	42,672	(14,547)	(34.09)%	105,955	134,167	(28,212)	(21.03)%
SOLGAR	67,705	75,513	(7,808)	(10.34)%	37,734	36,453	1,281	3.51%	105,439	111,966	(6,527)	(5.83)%
OTHER	232,472	243,518	(11,046)	(4.54)%	291,665	331,740	(40,075)	(12.08)%	524,137	575,258	(51,121)	(8.89)%
<b>TOTAL CONSUMER HEALTH CARE</b>	<b>\$ 1,658,102</b>	<b>\$ 1,661,860</b>	<b>\$ (3,758)</b>	<b>(0.23)%</b>	<b>\$ 753,957</b>	<b>\$ 779,239</b>	<b>\$ (25,282)</b>	<b>(3.24)%</b>	<b>\$ 2,412,059</b>	<b>\$ 2,441,099</b>	<b>\$ (29,040)</b>	<b>(1.19)%</b>

AHPC  
**WORLDWIDE NET REVENUE BY PRODUCTS**  
**TWELVE MONTHS ENDED DECEMBER 31, 2001**  
(000's)

	DOMESTIC				FOREIGN				TOTAL			
	YTD 2001	YTD 2000	DOLLAR CHANGE	PERCENT CHANGE	YTD 2001	YTD 2000	DOLLAR CHANGE	PERCENT CHANGE	YTD 2001	YTD 2000	DOLLAR CHANGE	PERCENT CHANGE
<b>TOTAL PHARMACEUTICALS</b>	\$ 7,370,946	\$ 6,383,191	\$ 987,755	15.47%	\$ 4,345,509	\$ 4,389,381	\$ (43,872)	(1.00)%	\$ 11,716,455	\$ 10,772,572	\$ 943,883	8.76%
<b>TOTAL CONSUMER HEALTH CARE</b>	1,658,102	1,661,860	(3,758)	(0.23)%	753,957	779,239	(25,282)	(3.24)%	2,412,059	2,441,099	(29,040)	(1.19)%
<b><i>TOTAL HEALTH CARE</i></b>	<b>\$ 9,029,048</b>	<b>\$ 8,045,051</b>	<b>\$ 983,997</b>	<b>12.23%</b>	<b>\$ 5,099,466</b>	<b>\$ 5,168,620</b>	<b>\$ (69,154)</b>	<b>(1.34)%</b>	<b>\$ 14,128,514</b>	<b>\$ 13,213,671</b>	<b>\$ 914,843</b>	<b>6.92%</b>

Note: The 2000 amounts have been restated in order to reflect the deconsolidation of Immunex, alliance revenue relating to co-promotion agreements between the Company and Immunex, and adoption of authoritative guidance reflecting certain rebates and sales incentives as reductions of revenues instead of selling and marketing expenses. In addition, certain other reclassification adjustments have been made in 2000 in order to conform to the 2001 presentation. In addition, for presentation purposes, the format of the report as it relates to pharmaceuticals has been modified, however, all products previously identified continue to be disclosed on the report. Ziact / Zebeta and generic products previously classified as "other" are now shown separately as a component of other.

**AMERICAN HOME PRODUCTS  
PREMARIN FAMILY  
NET REVENUE**

**4TH QUARTER**

	2001	2000	\$ Chg	% Chg	2001 % of Total
<b>Domestic:</b>					
Premarin	\$ 203,268	\$ 152,025	\$ 51,243	33.7%	57.5%
Prempro/phase	150,169	122,044	28,125	23.0%	42.5%
Premarin Family	353,437	274,069	79,368	29.0%	100.0%
<b>Foreign:</b>					
Premarin	37,394	36,059	1,335	3.7%	50.4%
Prempro/phase	36,793	32,748	4,045	12.4%	49.6%
Premarin Family	74,187	68,807	5,380	7.8%	100.0%
<b>Total:</b>					
Premarin	240,662	188,084	52,578	28.0%	56.3%
Prempro/phase	186,962	154,792	32,170	20.8%	43.7%
Premarin Family	\$ 427,624	\$ 342,876	\$ 84,748	24.7%	100.0%

**12 MONTHS ENDED**

	2001	2000	\$ Chg	% Chg	2001 % of Total
<b>Domestic:</b>					
Premarin	\$ 1,045,898	\$ 912,157	\$ 133,741	14.7%	58.2%
Prempro/phase	749,660	686,259	63,401	9.2%	41.8%
Premarin Family	1,795,558	1,598,416	197,142	12.3%	100.0%
<b>Foreign:</b>					
Premarin	139,742	141,856	(2,114)	-1.5%	50.3%
Prempro/phase	138,225	129,949	8,276	6.4%	49.7%
Premarin Family	277,967	271,805	6,162	2.3%	100.0%
<b>Total:</b>					
Premarin	1,185,640	1,054,013	131,627	12.5%	57.2%
Prempro/phase	887,885	816,208	71,677	8.8%	42.8%
Premarin Family	\$ 2,073,525	\$ 1,870,221	\$ 203,304	10.9%	100.0%

**YTD DECEMBER**

	2000	1999	\$ Chg	% Chg	2000 % of Total
<b>Domestic:</b>					
Premarin	\$ 912,157	\$ 954,483	\$ (42,326)	-4.4%	57.1%
Prempro/phase	686,259	562,511	123,748	22.0%	42.9%
Premarin Family	1,598,416	1,516,994	81,422	5.4%	100.0%
<b>Foreign:</b>					
Premarin	141,856	135,587	6,269	4.6%	52.2%
Prempro/phase	129,949	123,563	6,386	5.2%	47.8%
Premarin Family	271,805	259,150	12,655	4.9%	100.0%
<b>Total:</b>					
Premarin	1,054,013	1,090,070	(36,057)	-3.3%	56.4%
Prempro/phase	816,208	686,074	130,134	19.0%	43.6%
Premarin Family	\$ 1,870,221	\$ 1,776,144	\$ 94,077	5.3%	100.0%